Abbott Laboratories (NYSE:ABT - Get Free Report) Director Daniel Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Abbott Laboratories Stock Performance
Shares of NYSE ABT opened at $93.80 on Wednesday. The company has a current ratio of 1.58, a quick ratio of 1.18 and a debt-to-equity ratio of 0.19. The stock has a 50 day simple moving average of $105.19 and a 200-day simple moving average of $116.55. The company has a market cap of $163.37 billion, a PE ratio of 26.27, a P/E/G ratio of 1.55 and a beta of 0.79. Abbott Laboratories has a 12-month low of $90.72 and a 12-month high of $139.06.
Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.71% and a net margin of 13.90%.The business's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.
Abbott Laboratories Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 70.59%.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Purpose Unlimited Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC bought a new position in shares of Abbott Laboratories during the 4th quarter worth about $26,000. Institutional investors and hedge funds own 75.18% of the company's stock.
Key Headlines Impacting Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Analyst support: Citi reaffirmed its buy rating on ABT, reinforcing institutional confidence that the company’s long-term growth profile remains intact. Citi Sticks to Their Buy Rating for Abbott Laboratories (ABT)
- Positive Sentiment: Regulatory/portfolio catalyst: Abbott won FDA clearance and a CE Mark for its Ultreon™ 3.0 AI coronary imaging platform — a potential growth driver for high-margin cardiovascular devices and a tangible product-development win for medtech investors. Ultreon 3.0 FDA clearance and CE Mark
- Positive Sentiment: Insider buying: CFO Philip Boudreau bought shares (~2,200 at ~$91.50) and other insiders have recently purchased stock, which investors often read as management putting capital to work and a signal of confidence in the dividend and turnaround prospects. CFO Philip Boudreau Buys 2,200 Shares
- Neutral Sentiment: Dividend/defensive angle: Abbott remains a high-quality dividend payer (annualized ~$2.52) highlighted in income-focused commentary, which can support the stock among yield-seeking investors even amid volatility. How to Pick a Healthcare Stock That Can Weather Any Market
- Neutral Sentiment: Market opportunity context: Reports forecasting expansion in regional IVD markets (e.g., Saudi Arabia) underscore long-term demand for diagnostics platforms where Abbott competes, but these are broader-market tailwinds rather than immediate catalysts. Saudi Arabia IVD Market Report
- Negative Sentiment: Acquisition dilution and guidance cut: Abbott trimmed FY26 EPS guidance to $5.38–$5.58, citing about $0.20 of dilution from the $21B Exact Sciences acquisition — a primary reason the stock hit 52-week lows and continues to pressure sentiment. Q1 Earnings and Exact Sciences Acquisition Fallout
Wall Street Analysts Forecast Growth
ABT has been the subject of a number of recent analyst reports. The Goldman Sachs Group decreased their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a "buy" rating for the company in a research note on Wednesday, April 8th. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. Daiwa Securities Group lowered shares of Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price objective for the company. in a research note on Wednesday, April 22nd. Citigroup reduced their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a "buy" rating for the company in a research note on Friday, April 17th. Finally, Piper Sandler reduced their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has an average rating of "Moderate Buy" and a consensus target price of $119.43.
Get Our Latest Report on Abbott Laboratories
About Abbott Laboratories
(
Get Free Report)
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
